Through the new agreements, Cristal Therapeutics and McSAF will gain access to Lonza’s integrated bioconjugates offering and will be able to leverage Lonza’s expertise in developing and manufacturing bioconjugates
Exceeding the target of 1.50 lakh Ayushman Bharat - Health & Wellness Centres (AB-HWC) by 31 December, 2022, more than 1.54 lakh Sub Health Centres and Primary Health Centres have been transformed as AB-HWCs
Swiftmelt 1515-I meets performance requirements and secures skin attachment
Launch of Apollo Genomics Institutes would provide genetic counselling, tests, treatment and care for genetic disorders
Collaboration to generate and develop therapeutics for oncology and non-oncology conditions
NDM disorders are a group of rare, inherited neuromuscular disorders with an estimated prevalence of 1 case per 100,000 inhabitants in Spain, and are characterized by the inability to relax muscles following voluntary contraction (myotonia)
Moderna and Merck announced mRNA-4157/V940, in combination with KEYTRUDA, demonstrated a 44% reduction in the risk of disease recurrence or death in melanoma patients
The centre has initiated next generation sequencing (NGS) as a tool for undertaking studies on genomic epidemiology of pathogens
Dr. Jain is a biotechnology industry veteran with more than two decades of experience in pharmaceutical development across her time with ChemoCentryx, AbbVie, Abbott Laboratories, and G.D. Searle and Co
Subscribe To Our Newsletter & Stay Updated
